Characterization and Metabolic Targeting of Human Pathogenic Effector Th2 Cells

Immunology Interest Group Dr. Prussin is currently Chair of the Board of Directors of the American Board of Allergy and Immunology. Prior to July 2015, Dr. Prussin was a Staff Clinician, Clinical Investigator, and Associate Director of the NIH Allergy and Immunology Fellowship Training Program, within the Laboratory of Allergic Diseases, NIAID. He received his M.D. and his internal medicine training at the Keck School of Medicine of the University of Southern California (USC). He came to NIH for a postdoctoral fellowship with Ron Schwartz, after which he completed his Allergy and Immunology Clinical Fellowship at NIH working with Dean Metcalfe. Dr. Prussin was one of the first investigators to apply intracellular cytokine staining to human disease in work demonstrating the existence of human Th1 and Th2 cells directly ex vivo. He uses a translational approach to examine important immunological questions using human disease as a model system to interrogate the biology of human allergic effector cells, most notably Th2 cells, basophils, and mast cells. Dr. Prussin’s work is notable for identifying FcεRI on dendritic cell subpopulations and demonstrating its modulation by anti-IgE treatment. His recent work has resulted in a series of papers focusing on human Th2 cell heterogeneity. This work establishes the existence of discreet Th2 subpopulations, characterizes their function, defines specific phenotypic markers, and identifies the mTORC1 pathway as a potential means to ta...

Source: Videocast - All Events - October 13, 2015 Category: Journals (General) Tags: Upcoming Events Source Type: video